VBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Valion Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.16−0.01 (-0.85%)
Close on Oct 19, 2026
- Market cap
- $3.92M
- P/E (TTM)
- –
- Dividend yield
- –
Valion Bio statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Valion Bio | Industry median |
|---|---|---|
| Market Cap | $4.82M | $166.30M |
| Enterprise Value | $2.71M | $88.19M |
| PB Ratio | 1.13 | 2.03 |
Income (trailing twelve months)
| Measure | Valion Bio | Industry median |
|---|---|---|
| Operating Income | -$16.52M | -$21.40M |
| Net Income | -$18.75M | -$22.46M |
| EBITDA | -$16.52M | -$16.91M |
| EPS (Diluted) | -$7.77 | -$0.83 |
Returns
| Measure | Valion Bio | Industry median |
|---|---|---|
| Return on Equity (ROE) | -472.7% | -53.2% |
| Return on Assets (ROA) | -101.4% | -40.9% |
| Return on Invested Capital (ROIC) | -562.3% | -32.4% |
| Return on Capital Employed (ROCE) | -56.1% | -38.1% |
Balance sheet
| Measure | Valion Bio | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $2.11M | $61.43M |
| Net Cash (Debt) | $2.11M | $15.35M |
| Net Cash Per Share | $0.51 | $0.66 |
| Equity (Book Value) | $4.25M | $49.09M |
| Book Value Per Share | $1.02 | $1.37 |
| Tangible Book Value | -$1.45M | $23.52M |
| Working Capital | $336.00K | $76.81M |
Financial position
| Measure | Valion Bio | Industry median |
|---|---|---|
| Current Ratio | 1.11 | 3.34 |
| Quick Ratio | 0.69 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Valion Bio | Industry median |
|---|---|---|
| Operating Cash Flow | -$14.58M | -$12.35M |
| Capital Expenditures | -$99.00K | -$1.08M |
| Free Cash Flow | -$14.67M | -$20.22M |
| FCF Per Share | -$3.53 | -$0.42 |
Efficiency
| Measure | Valion Bio | Industry median |
|---|---|---|
| Profits Per Employee | -$360.58K | -$703.34K |
| Employee Count | 52 | 74 |
Dividends and yields
| Measure | Valion Bio | Industry median |
|---|---|---|
| Earnings Yield | -389.3% | -23.3% |
| FCF Yield | -304.7% | -8.72% |
Shares
| Measure | Valion Bio | Industry median |
|---|---|---|
| Shares Outstanding | 4,151,920 | 58,127,000 |
| Shares Change (YoY) | 308.9% | 10.9% |
| Shares Change (QoQ) | 44.2% | 0.54% |
| Float | 3,953,930 | 49,136,700 |
| Shares Held by Insiders | 4.77% | 11.6% |
Scores
| Measure | Valion Bio | Industry median |
|---|---|---|
| Altman Z-Score | -4.39 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Valion Bio's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.